Cyplasin Biomedical Ltd., announces Licensing of Cyplasin technology
Cyplasin Biomedical Ltd., announced that it has completed the granting of a worldwide exclusive license to Bioxen Ltd for its Cyplasin technology for therapeutic use. Under terms of the license Bioxen will further develop the Cyplasin protein for use in skin cancer, melanoma and other potential therapeutic uses.
Financial terms were not disclosed but the license includes a financial upfront payment with an option for Bioxen to purchase the Cyplasin IP at some future date.
Cyplasin Biomedical Ltd has retained the non therapeutic rights to the technology and in the event such products are developed Cyplasin will pay a small single digit royalty to Bioxen Ltd. In the event Bioxen exercises its option to purchase the Cyplasin IP, Cyplasin will be granted an irrevocable, fully paid, world wide exclusive, license to all non therapeutic products.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.